keyword
MENU ▼
Read by QxMD icon Read
search

Clinical Trial And Colorectal Cancer

keyword
https://read.qxmd.com/read/30764882/expert-consensus-on-multidisciplinary-therapy-of-colorectal-cancer-with-lung-metastases-2019-edition
#1
REVIEW
Jian Li, Ying Yuan, Fan Yang, Yi Wang, Xu Zhu, Zhenghang Wang, Shu Zheng, Desen Wan, Jie He, Jianping Wang, Yi Ba, Chunmei Bai, Li Bai, Wei Bai, Feng Bi, Kaican Cai, Muyan Cai, Sanjun Cai, Gong Chen, Keneng Chen, Lin Chen, Pengju Chen, Pan Chi, Guanghai Dai, Yanhong Deng, Kefeng Ding, Qingxia Fan, Weijia Fang, Xuedong Fang, Fengyi Feng, Chuangang Fu, Qihan Fu, Yanhong Gu, Yulong He, Baoqing Jia, Kewei Jiang, Maode Lai, Ping Lan, Enxiao Li, Dechuan Li, Jin Li, Leping Li, Ming Li, Shaolei Li, Yexiong Li, Yongheng Li, Zhongwu Li, Xiaobo Liang, Zhiyong Liang, Feng Lin, Guole Lin, Hongjun Liu, Jianzhong Liu, Tianshu Liu, Yunpeng Liu, Hongming Pan, Zhizhong Pan, Haiping Pei, Meng Qiu, Xiujuan Qu, Li Ren, Zhanlong Shen, Weiqi Sheng, Chun Song, Lijie Song, Jianguo Sun, Lingyu Sun, Yingshi Sun, Yuan Tang, Min Tao, Chang Wang, Haijiang Wang, Jun Wang, Shubin Wang, Xicheng Wang, Xishan Wang, Ziqiang Wang, Aiwen Wu, Nan Wu, Lijian Xia, Yi Xiao, Baocai Xing, Bin Xiong, Jianmin Xu, Jianming Xu, Nong Xu, Ruihua Xu, Zhongfa Xu, Yue Yang, Hongwei Yao, Yingjiang Ye, Yonghua Yu, Yueming Yu, Jinbo Yue, Jingdong Zhang, Jun Zhang, Suzhan Zhang, Wei Zhang, Yanqiao Zhang, Zhen Zhang, Zhongtao Zhang, Lin Zhao, Ren Zhao, Fuxiang Zhou, Jian Zhou, Jing Jin, Jin Gu, Lin Shen
The lungs are the second most common site of metastasis for colorectal cancer (CRC) after the liver. Rectal cancer is associated with a higher incidence of lung metastases compared to colon cancer. In China, the proportion of rectal cancer cases is around 50%, much higher than that in Western countries (nearly 30%). However, there is no available consensus or guideline focusing on CRC with lung metastases. We conducted an extensive discussion and reached a consensus of management for lung metastases in CRC based on current research reports and the experts' clinical experiences and knowledge...
February 14, 2019: Journal of Hematology & Oncology
https://read.qxmd.com/read/30753571/observational-study-of-first-line-chemotherapy-including-cetuximab-in-patients-with-metastatic-colorectal-cancer-coral-trial
#2
Kei Muro, Michio Itabashi, Hiroki Hashida, Toshiki Masuishi, Hiroyuki Bando, Tadamichi Denda, Takeharu Yamanaka, Yasuo Ohashi, Kenichi Sugihara
Objective: We aimed to clarify the clinical practice and outcomes of first-line cetuximab-containing chemotherapy in patients with metastatic colorectal cancer. Efficacy and safety were evaluated in each group classified by the European Society for Medical Oncology Guidelines 2012. Methods: This prospective observational study included patients with previously untreated metastatic colorectal cancer from 158 centers in Japan who started first-line cetuximab-containing chemotherapy from January 2012 to June 2013 and were followed for up to 3 years...
February 8, 2019: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/30741437/health-benefits-of-resveratrol-evidence-from-clinical-studies
#3
REVIEW
Akhand Pratap Singh, Rachna Singh, Sumit Singh Verma, Vipin Rai, Catherine H Kaschula, Pralay Maiti, Subash Chandra Gupta
Resveratrol is a polyphenolic nutraceutical that exhibits pleiotropic activities in human subjects. The efficacy, safety, and pharmacokinetics of resveratrol have been documented in over 244 clinical trials, with an additional 27 clinical trials currently ongoing. Resveretrol is reported to potentially improve the therapeutic outcome in patients suffering from diabetes mellitus, obesity, colorectal cancer, breast cancer, multiple myeloma, metabolic syndrome, hypertension, Alzheimer's disease, stroke, cardiovascular diseases, kidney diseases, inflammatory diseases, and rhinopharyngitis...
February 11, 2019: Medicinal Research Reviews
https://read.qxmd.com/read/30739838/total-neoadjuvant-approach-with-folfoxiri-plus-bevacizumab-followed-by-chemoradiotherapy-plus-bevacizumab-in-locally-advanced-rectal-cancer-the-trust-trial
#4
Gianluca Masi, Caterina Vivaldi, Lorenzo Fornaro, Sara Lonardi, Piero Buccianti, Aldo Sainato, Lorenzo Marcucci, Angelo Martignetti, Emanuele Damiano Luca Urso, Maura Castagna, Gabriella Fontanini, Francesca Bergamo, Gianna Musettini, Lucio Urbani, Elisa Sensi, Riccardo Balestri, Sabrina Montrone, Francesco Pasqualetti, Chiara Cremolini, Antonello Di Paolo, Vittorina Zagonel, Alfredo Falcone
BACKGROUND: Neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC) does not achieve effective control of distant metastases. Induction chemotherapy is a promising strategy, and bevacizumab (BV) could improve the results of CRT. 5-Fluorouracil, oxaliplatin and irinotecan (FOLFOXIRI) plus BV is a treatment option in metastatic colorectal cancer. We evaluate feasibility and efficacy of neoadjuvant treatment comprising induction FOLFOXIRI plus BV followed by CRT with fluoropyrimidines plus BV...
February 7, 2019: European Journal of Cancer
https://read.qxmd.com/read/30739558/quality-of-life-and-cost-of-strategies-of-two-chemotherapy-lines-in-metastatic-colorectal-cancer-results-of-the-ffcd-2000-05-trial
#5
Benjamin Lacas, Olivier Bouché, Pierre-Luc Etienne, Mohamed Gasmi, Patrick Texereau, Dany Gargot, Catherine Lombard-Bohas, Ahmed Azzedine, Bernard Denis, Patrick Geoffroy, Dominique Auby, Pierre Michel, Jean-Pierre Pignon, Côme Lepage, Michel Ducreux, Isabelle Borget
OBJECTIVES: This study compared the cost and quality of life (QoL) of 407 advanced colorectal cancer patients, randomly assigned to receive LV5FU2 followed by FOLFOX6 (sequential strategy) or FOLFOX6 followed by FOLFIRI (combination strategy). METHODS: Costs were compared from the French health insurance perspective, until the end of 2nd line of treatment. Consumed resources, collected during the trial, included medicines, hospitalisations, examinations and transportation...
February 9, 2019: Expert Review of Pharmacoeconomics & Outcomes Research
https://read.qxmd.com/read/30737018/-msi-metastatic-solid-tumors-treatment-and-immunotherapies
#6
REVIEW
Clémentine Bouchez, Emmanuelle Kempf, Christophe Tournigand
Checkpoints inhibitors are known to induce striking tumor responses in advanced MSI colorectal cancers, which used to be related to a poor clinical outcome. The incidence of the MSI phenotype is highly heterogeneous across non-colorectal cancers. The highest incidence rates are found in endometrioid forms of uterine cancers and in gastric tumors (20 to 40 % and 10 to 33 %, respectively). The association between a "MSI" tumor phenotype and other clinical or biological tumor characteristics is still under debate...
February 5, 2019: Bulletin du Cancer
https://read.qxmd.com/read/30725411/clinical-studies-of-methionine-restricted-diets-for-cancer-patients
#7
Robert M Hoffman
Methionine (MET) restriction (MR) has been shown to arrest cancer growth and sensitizes tumors to chemotherapy. MR total parenteral nutrition (MR TPN) with a chemotherapy-containing amino acid solution ("AO-90") (lacking both MET and L-cysteine[CYS]) showed synergistic effects with 5-fluorouracil (5-FU) in tumor-bearing rats and in a Phase I clinical trial with gastrointestinal tract cancers compared to 5-FU in a MET-containing TPN. All gastric cancer patients underwent gastrectomy. Resected tumors in the AO-90 group showed significant reduction of cancer histologically, while almost no effect was seen in the control group...
2019: Methods in Molecular Biology
https://read.qxmd.com/read/30723407/platelet-derived-microparticles-from-obese-individuals-characterization-of-number-size-proteomics-and-crosstalk-with-cancer-and-endothelial-cells
#8
Rosalia Grande, Melania Dovizio, Simone Marcone, Paulina B Szklanna, Annalisa Bruno, H Alexander Ebhardt, Hilary Cassidy, Fionnuala Ní Áinle, Anna Caprodossi, Paola Lanuti, Marco Marchisio, Geltrude Mingrone, Patricia B Maguire, Paola Patrignani
Rationale: Obesity is a risk factor for atherothrombosis and various cancers. However, the mechanisms are not yet completely clarified. Objectives: We aimed to verify whether the microparticles (MPs) released from thrombin-activated platelets differed in obese and non-obese women for number, size, and proteomics cargo and the capacity to modulate in vitro the expression of (i) genes related to the epithelial to mesenchymal transition (EMT) and the endothelial to mesenchymal transition (EndMT), and (ii) cyclooxygenase (COX)-2 involved in the production of angiogenic and inflammatory mediators...
2019: Frontiers in Pharmacology
https://read.qxmd.com/read/30722106/differences-in-clinical-features-and-oncologic-outcomes-between-metastatic-right-and-left-colon-cancer
#9
Kwangmin Kim, Young-Wan Kim, Hongjin Shim, Bo-Ra Kim, Hye Youn Kwon
Approximately 20% to 25% of patients with colorectal cancer (CRC) have distant organ metastasis at the time of initial diagnosis. The primary tumor location has been suggested as a prognostic factor for patients with metastatic CRC. In recent years, the distinction between right colon cancer (RCC) and left colon cancer (LCC) has been brought into focus due to their different outcomes, prognoses, and clinical responses to chemotherapy. In this article we aimed to review the underlying differences between metastatic RCC and LCC in terms of epidemiology, clinical features, and oncologic outcomes...
December 2018: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://read.qxmd.com/read/30719690/early-tumor-shrinkage-after-first-line-medical-treatment-of-metastatic-colorectal-cancer-a-meta-analysis
#10
REVIEW
Giuseppe A Colloca, Antonella Venturino, Domenico Guarneri
BACKGROUND: Early tumor shrinkage (ETS) is a response-related endpoint of clinical trials of chemotherapy (CHT) of patients with metastatic colorectal cancer (mCRC). It identifies a dimensional reduction of tumor size by at least 20-30% after 6-8 weeks of CHT. METHODS: A literature search of randomized trials of systemic treatment including CHT with or without antiangiogenics or anti-EGFR inhibitors in patients with mCRC has been conducted, and studies reporting the results of the relationship of ETS with overall survival (OS) and progression-free survival (PFS) were selected...
February 4, 2019: International Journal of Clinical Oncology
https://read.qxmd.com/read/30719102/the-impact-of-the-glasgow-prognostic-score-on-survival-in-second-line-chemotherapy-for-metastatic-colorectal-cancer-patients-with-braf-v600e-mutation
#11
Seiichiro Mitani, Hiroya Taniguchi, Keiji Sugiyama, Toshiki Masuishi, Kazunori Honda, Yukiya Narita, Shigenori Kadowaki, Takashi Ura, Masashi Ando, Masahiro Tajika, Yasushi Yatabe, Kei Muro
Background: BRAF (v-raf murine sarcoma viral oncogene homolog B1) V600E mutant colorectal cancer is associated with short survival. Recently, clinical trials have been conducted to improve outcomes of second or later lines of chemotherapy. However, there is a paucity of reference data pertaining to outcomes of second-line chemotherapy and prognostic factors that are relevant only to BRAF mutant patients. Patients and methods: We retrospectively reviewed metastatic colorectal cancer patients with BRAF V600E mutation who underwent second-line chemotherapy between January 2007 and March 2017...
2019: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/30711862/effects-of-prebiotics-on-immunologic-indicators-and-intestinal-microbiota-structure-in-perioperative-colorectal-cancer-patients
#12
Xiaoliang Xie, Yaqin He, Hai Li, Dong Yu, Li Na, Ting Sun, Dong Zhang, Xinrong Shi, Yuhan Xia, Tao Jiang, Shikuo Rong, Shaoqi Yang, Xiaoqiang Ma, Guangxian Xu
OBJECTIVE: The aim of the present study was to investigate the effects of prebiotics (containing fructooligosaccharides, xylooligosaccharides, polydextrose, and resistant dextrin) intake on immune function and intestinal microbiota structure in perioperative patients with colorectal cancer (CRC). METHODS: A randomized, double-blind, no-treatment parallel control clinical trial involving 140 perioperative patients (90 men and 50 women, aged 40-75 y) with CRC was performed...
November 29, 2018: Nutrition
https://read.qxmd.com/read/30709384/predictors-for-use-of-psychosocial-services-in-patients-with-metastatic-colorectal-cancer-receiving-first-line-systemic-treatment
#13
Claudia S E W Schuurhuizen, Annemarie M J Braamse, Inge R H M Konings, Henk M W Verheul, Joost Dekker
BACKGROUND: Patients with advanced disease experience high levels of psychological distress, yet there is low uptake of psychosocial services offered to patients who screened positive for distress. In this study we aimed to identify predictors for use of psychosocial services in patients with metastatic colorectal cancer (mCRC) receiving first line chemotherapy enrolled in a prospective cluster randomized trial (CRT). METHODS: Patients completed measures on psychological distress, physical distress, and quality of life at baseline...
February 1, 2019: BMC Cancer
https://read.qxmd.com/read/30706121/tumor-size-responses-to-first-line-is-a-predictor-of-overall-survival-in-metastatic-colorectal-cancer
#14
Lola-Jade Palmieri, Amina Fihri, Solène Doat, Olivier Dubreuil, Gilles Manceau, Mehdi Karoui, Mathilde Wagner, Olivier Lucidarme, Jean-Baptiste Bachet
OBJECTIVES: Early tumor shrinkage (ETS) has been reported to be associated with survival of metastatic colorectal cancer (mCRC) patients. Our aim was to analyze long-term tumor-size evolution, according to early mCRC best responses during the first-line therapy, to evaluate first best response-survival links. METHODS: Sixty-five patients with unresectable mCRCs, treated between 2010 and 2015, were included retrospectively in this descriptive monocenter study and grouped according to their RECIST 1...
January 31, 2019: European Radiology
https://read.qxmd.com/read/30706011/stereotactic-ablative-radiation-therapy-for-unresectable-colorectal-oligometastases
#15
Philip Sutera, Ronny Kalash, David A Clump, David D'Ambrosio, Alina Mihai, Steven A Burton, Dwight E Heron
Purpose: Patients with oligometastatic colorectal cancer have demonstrated excellent clinical outcomes with surgical resection of hepatic and pulmonary metastases. Stereotactic ablative radiation therapy (SABR) has emerged as an alternative local therapy for nonsurgical candidates. Herein, we report the oncologic and patient-reported quality-of-life (PR-QoL) outcomes for a subset of patients with oligometastatic colorectal cancer who were treated in a prospective phase 2 multicenter clinical trial...
January 2019: Advances in Radiation Oncology
https://read.qxmd.com/read/30704795/outcomes-of-prostatectomy-versus-radiation-therapy-in-the-management-of-clinically-localized-prostate-cancer-patients-within-the-plco-trial
#16
Omar Abdel-Rahman
BACKGROUND: The objective of the study was to evaluate the outcomes of clinically localized prostate cancer treated with prostatectomy versus radiation therapy within the context of a prospective prostate cancer screening study. PATIENTS AND METHODS: Within the PLCO (Prostate, Lung, Colorectal, and Ovary) trial, patients who were diagnosed with clinically localized prostate cancer and subsequently received treatment with prostatectomy or radiation therapy (with or without hormonal treatment) were included...
January 4, 2019: Clinical Genitourinary Cancer
https://read.qxmd.com/read/30703787/-looking-back-2018-focused-on-colorectal-cancer
#17
Jian Cai, Lei Wang
Colorectal cancer is one of the most common malignant tumors, and its incidence and mortality are increasing year by year in China. In 2018, for the first time, the FIT-DNA test was written into the expert consensus as the recommended screening technology in China. As the core technology of colorectal cancer screening, colonoscopy for right colon cancer is further supported. With the application of artificial intelligence technology in colonoscopy, the efficiency and accuracy of screening will be greatly improved...
January 25, 2019: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://read.qxmd.com/read/30700474/capeox-perioperative-chemotherapy-versus-postoperative-chemotherapy-for-locally-advanced-resectable-colon-cancer-protocol-for-a-two-period-randomised-controlled-phase-iii-trial
#18
Fangqi Liu, Tong Tong, Dan Huang, Weitang Yuan, Dechuan Li, Jianjiang Lin, Sanjun Cai, Ye Xu, Wenbin Chen, Yueming Sun, Jing Zhuang
INTRODUCTION: Adjuvant chemotherapy with the CapeOX regimen is now widely used for treating colorectal cancer. However, prior studies have demonstrated better efficacy of pre-operative/neoadjuvant chemotherapy without increase of safety risks. METHODS AND ANALYSIS: This multicentre, open-label, parallel-group, randomised, controlled, phase III study aims to compare the efficacy and safety of perioperative CapeOX chemotherapy with the postoperative one for treating patients with locally advanced R0 resectable colon cancers in China...
January 29, 2019: BMJ Open
https://read.qxmd.com/read/30694992/reassessing-the-role-of-liver-transplantation-for-patients-with-metastatic-colorectal-cancer-to-the-liver
#19
Pranit Chotai, Lea Matsuoka
PURPOSE OF REVIEW: Early studies reported poor survival rates following liver transplantation for metastatic colorectal cancer to the liver and liver transplantation has thus traditionally been contraindicated for these patients. However, improvements in liver transplantation outcomes, immunosuppression and the treatment of colorectal cancer warrant a reassessment of the role of liver transplantation for metastatic colorectal cancer. RECENT FINDINGS: The literature on this topic is sparse, the majority of publications being isolated cases of liver transplantation for patients with metastatic colorectal cancer to the liver...
January 28, 2019: Current Opinion in Organ Transplantation
https://read.qxmd.com/read/30690930/efficacy-and-safety-of-folfiri-aflibercept-in-second-line-treatment-of-metastatic-colorectal-cancer-in-a-real-world-population-prognostic-and-predictive-markers
#20
Ana Fernández Montes, Nieves Martínez Lago, Marta Covela Rúa, Juan de la Cámara Gómez, Paula González Villaroel, José Carlos Méndez Méndez, Mónica Jorge Fernández, Mercedes Salgado Fernández, Margarita Reboredo López, Guillermo Quintero Aldana, María Luz Pellón Augusto, Begoña Graña Suárez, Jesús García Gómez
PURPOSE: The phase III VELOUR trial demonstrated efficacy with combined FOLFIRI-aflibercept in patients with metastatic colorectal cancer previously treated with oxaliplatin with or without bevacizumab versus placebo. The effect of FOLFIRI-aflibercept in routine clinical practice was evaluated. METHODS/PATIENTS: Overall survival (OS), progression-free survival (PFS), response and safety were analysed for 78 patients treated with FOLFIRI-aflibercept at six GITuD institutions...
January 28, 2019: Cancer Medicine
keyword
keyword
171059
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"